Evidence map›Paper›PMID 42856979›Full record

ArticleCirculation reports2026

Safety and Efficacy of Ponatinib for Pulmonary Tumor Thrombotic Microangiopathy.

Kimi Sato, Naoto Kawamatsu, Masayoshi Yamamoto, Tomoko Machino-Ohtsuka, Tatsuhiro Sakamoto, Takeshi Yamada, Yoshiyuki Yamamoto, Masato Homma, Bryan J Mathis, Ikuo Sekine and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kimi SatoDepartment of Cardiology, Institute of Medicine, University of Tsukuba Ibaraki Japan.
Naoto KawamatsuDepartment of Cardiology, Institute of Medicine, University of Tsukuba Ibaraki Japan.
Masayoshi YamamotoDepartment of Cardiology, Institute of Medicine, University of Tsukuba Ibaraki Japan.
Tomoko Machino-OhtsukaDepartment of Cardiology, Institute of Medicine, University of Tsukuba Ibaraki Japan.
Tatsuhiro SakamotoDepartment of Hematology, Institute of Medicine, University of Tsukuba Ibaraki Japan.
Takeshi YamadaDepartment of Gastroenterology, Institute of Medicine, University of Tsukuba Ibaraki Japan.
Yoshiyuki YamamotoDepartment of Gastroenterology, Institute of Medicine, University of Tsukuba Ibaraki Japan.
Masato HommaDepartment of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba Ibaraki Japan.
Bryan J MathisDepartment of Cardiovascular Surgery, Institute of Medicine, University of Tsukuba Ibaraki Japan.
Ikuo SekineDepartment of Medical Oncology, Institute of Medicine, University of Tsukuba Ibaraki Japan.
Tomoko IshizuDepartment of Cardiology, Institute of Medicine, University of Tsukuba Ibaraki Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We evaluated the safety and efficacy of ponatinib, a multi-target tyrosine kinase inhibitor, for pulmonary tumor thrombotic microangiopathy (PTTM). Methods and Results: We conducted a single-center, open-label, single-arm, prospective study; 3 patients associated with ovarian, breast, and gastric carcinomas were enrolled and received oral ponatinib for 2 weeks. All died from PTTM progression with no severe ponatinib-related adverse events. Conclusions: This study failed to demonstrate ponatinib efficacy. Further studies may evaluate the effect of different biochemical targets on PTTM.

Indexed as

Multi-target tyrosine kinase inhibitorPonatinibPulmonary hypertensionPulmonary tumor thrombotic microangiopathy

Identifiers

PMID42856979
PMCPMC13649527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.